ELTX
Elicio Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.41
−3.60%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 289.0K | 1.1M | 1.2M | 1.2M | 1.1M |
| Gross Profit | (289.0K) | (1.1M) | (1.2M) | (1.2M) | (1.1M) |
| Operating Expenses | |||||
| R&D Expense | 23.6M | 24.9M | 33.7M | 22.7M | 17.0M |
| SG&A Expense | 14.2M | 12.8M | 11.3M | 11.9M | 5.6M |
| General & Admin Expense | 14.2M | 12.8M | 11.3M | 11.9M | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (243.0K) | (1.1M) | (1.2M) | — | — |
| Total Operating Expenses | 37.6M | 36.6M | 43.8M | 34.6M | 22.7M |
| Cost and Expenses | 37.9M | 37.7M | 45.0M | 35.7M | 23.7M |
| Operating Income (EBIT) | (37.9M) | (37.7M) | (45.0M) | (35.7M) | (23.7M) |
| Non-Operating | |||||
| Interest Income | 693.0K | 776.0K | 777.0K | 373.0K | 64.8K |
| Interest Expense | 1.6M | 1.1M | 455.0K | 1.1M | 3.6M |
| Net Interest Income | (887.0K) | (357.0K) | 322.0K | (686.0K) | (3.5M) |
| Other Non-Op Income/Expense | 77.0K | (1.9M) | (6.9M) | 550.0K | (4.5M) |
| Non-Operating Income (excl Interest) | 3.4M | 724.0K | 6.5M | (1.6M) | 878.0K |
| EBT (Pre-Tax Income) | (37.8M) | (39.6M) | (51.9M) | (35.2M) | (28.2M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (37.8M) | (39.6M) | (51.9M) | (35.2M) | (28.2M) |
| Earnings from Cont. Ops | (37.8M) | (39.6M) | (51.9M) | (35.2M) | (28.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (37.8M) | (39.6M) | (51.9M) | (35.2M) | (28.2M) |
| Per Share | |||||
| Basic EPS | ($2.13) | ($2.58) | ($4.25) | ($6.96) | ($9.10) |
| Diluted EPS | ($2.13) | ($2.58) | ($4.25) | ($6.96) | ($9.10) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 19.2M | 15.3M | 12.2M | 5.1M | 3.1M |
| Diluted Shares Outstanding | 19.2M | 15.3M | 12.2M | 5.1M | 3.1M |
| Profitability Metrics | |||||
| EBITDA | (40.5M) | (37.3M) | (50.3M) | (33.0M) | (23.6M) |
| D&A | 858.0K | 1.1M | 1.2M | 1.2M | 1.1M |
| EBIT | (41.4M) | (38.4M) | (51.4M) | (34.1M) | (24.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026